UNSPSC 51282812: Metronidazole phosphate

This classification denotes an antiprotozoal agent and antimicrobial with the molecular formula C6H10N3O6P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier L500PR95QA, chemically known as 1h-imidazole-1-ethanol, 2-methyl-5-nitro-, dihydrogen phosphate (ester) but more generally known as metronidazole phosphate, which bears US NIH Compound Identifier 51794. Most nations, for tariff and trade purposes, schedule metronidazole phosphate under HS 29332990 and SITC 51573.

As of Q4 2014, METRONIDAZOLE PHOSPHATE remains US FDA's Preferred Term for this commodity. Metronidazole phosphate bears US NLM identifiers UMLS ID C0887130 and NCI Concept Code C90619. SMILES: CC1NCC(N1CCOP(=O)(O)O)[N+](=O)[O-].

UNSPSC 51282812 Metronidazole phosphate is a Commodity code representing a single pharmaceutical product line. However, the recent state and local procurement activity tagged under this code does not align with metronidazole phosphate; instead, opportunities solicited under the code involve unrelated pharmaceutical products—antibiotics (Doxycycline Hyclate, Ciprofloxacin Hydrochloride) and emergency medical supplies (Naloxone and drug deactivation systems). The code shows a mismatch between its nominal scope and the work actually being procured, suggesting either a classification error in source records or inconsistent tagging by issuing bodies. State and local health departments and county health authorities are the primary users of this code when tagged, typically purchasing pharmaceutical inventory and emergency medical supplies through competitive bidding and cooperative purchasing arrangements.

Recent activity appears limited. The Illinois Department of Public Health awarded a $2,999,999.11 piggyback pharmaceutical contract to Chartwell Rx LLC through the MMCAP Infuse cooperative on August 28, 2026, for Doxycycline Hyclate and Ciprofloxacin Hydrochloride with a 12-month initial term and two renewal options, but this was a completed award rather than an open solicitation. Seminole County, Florida released an IFB on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually with quarterly deliveries, with a response deadline of July 26, 2026. Both opportunities involved state and local health procurement entities in the Southeast and Midwest, but the code's nominal scope and actual tagged procurement diverge significantly, limiting relevance for business development targeting metronidazole phosphate specifically.